Wednesday, June 22, 2022 Daily Archives

Delivering on the Promise of Bispecifics: State-of-the-Art Bispecific Antibody Development

by , , and

Bispecific antibodies (bsAbs) have transformed the field of immunotherapy. However, moving these life-changing therapeutics from the bench to the clinic can be time-consuming and costly. Further, challenges such as aggregation, degradation, fragmentation, and denaturation may ultimately hinder a program from advancing to the clinic. Partnering with a CDMO with relevant experience and technologies can be critical for safely and cost-effectively manufacturing bispecific antibodies. With Selexis’s cell line technology and KBI Biopharma’s manufacturing and analytics, we lead the industry in technologies…

June 22, 2022

Stability Assessment of mRNA Formulations – Toward the Development of Degradation Assays for mRNA-based Vaccines

by

This webcast features: Caio Henrique Barros, PhD, Research Scientist, National Institute for Bioprocessing Research and Training & James Geiger, PhD, Field Application Scientist, PerkinElmer. The COVID-19 pandemic has demonstrated the potential of mRNA vaccines to protect against infectious diseases. These unprecedented circumstances have also highlighted the instability of the mRNA molecule, which required the first COVID vaccines to be distributed at ultracold temperatures. This limitation has intensified efforts to develop mRNA formulations that are sufficiently stable at room temperature. Dried…

June 22, 2022

LentiVector platform: The first and leading commercial lentiviral-based gene delivery system

by

Oxford Biomedica’s LentiVector platform, which delivered the first FDA and EMA approved CAR-T cell therapy, enables the successful development of breakthrough gene and cell-based medicines. Discover more about the platform and our long and broad clinical and commercial track record, which spans over 25 years. Oxford Biomedica’s LentiVector platform enables the successful development of breakthrough gene and cell-based medicines. We have a long and broad clinical and commercial track record in the gene therapy field spanning over 25 years. Our…

June 22, 2022

VIVEbiotech Spain plant fully operational after GMP accreditation

by

VIVEbiotech says its facility in San Sebastian is fully operational after it received renewal of its GMP accreditation for a further three years. Contract development manufacturing organization (CDMO) VIVEbiotech claims the good manufacturing practice (GMP) accreditation means it is now certified for in vivo applications as well as ex vivo. Additionally, the CDMO’s capabilities will continue to be expanded through the incorporation of automated processes. VIVEbiotech says that it is looking at automation as a potential solution to cost challenges…

June 22, 2022

Invetech launches closed autologous cell therapy tech

by

Invetech says its Korus technology will offer industry an autologous cell therapy system that provides an option with minimal tech transfer challenges. With the Korus system launched this week, Invetech is targeting autologous cell therapy developers, including those in the CAR-T, TIL, NK, DC therapeutics areas, who are looking to start their cell therapy manufacturing process with cleaner lymphocyte or monocyte populations – and improve their overall manufacturing yield. The closed system includes elutriation and cell wash using gentle counterflow…

June 22, 2022

CGT Catapult partnership to develop AAV gene therapies for dementia

by

The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have partnered to drive the development of adeno-associated virus (AAV) based gene therapies for dementia. According to CGT Catapult, dementia is one of the leading causes of mortality in the UK and while treatments are emerging and improving, with no effective treatment options currently available for neurodegenerative conditions, dementia-related deaths are continuing to increase. The UK DRI’s role is to develop an understanding of…

June 22, 2022